Recently, a randomized trial was conducted with the PD-L1 and CTLA4 inhibitors durvalumab and tremelimumab, respectively, for supportive pMMR/MSS CRC therapy (58). This evidence concerns the gene CTLA4 and colorectal carcinoma.